Bristol Myers Squibb's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Bristol Myers Squibb's ROA in the second quarter of 2026?
Bristol myers Squibb Company achieved a return on average assets (ROA) of 10.28 % in its second quarter of 2026, this is above BMY's average return on assets of 8.34%.
Bristol Myers Squibb Companys assets during the 12 months ending in the second quarter of 2026 are valued at $90 billion

ROA has improved compared to 7.89% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 94 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 779, from total ROA ranking in the first quarter of 2026 at 953.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-8.42 %	-6.04 %	2.34 %	7.58 %	3.67 %
Y / Y Net Income Change	152.55 %	8.77 %	1327.63 %	80.66 %	-22.03 %
Net Income (TTM) in million	9,274	7,271	7,055	6,046	5,066
Return On Assets (TTM)	10.28 %	7.89 %	7.54 %	6.49 %	5.54 %
BMY's Total Ranking	# 779	# 953	# 960	# 1103	# 1057
Total Assets (TTM) in million	86,708	86,842	90,434	96,889	94,676
Seq. Total Assets Change	-0.15 %	-3.97 %	-6.66 %	2.34 %	2.43 %
Seq. Net Income Change	23.82 %	146.82 %	-50.57 %	67.17 %	-46.67 %

BMY's 5 Years Annual ROA >> Back to BMY Management Effectiveness >> Compare BMY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 39
Sector	# 95
Overall	# 580

Return On Assets Statistics
High	Average	Low
34.99 %	8.34 %	-9.4 %
(March 31, 2010)		(Dec 31 2024)

Financial Statements
Bristol Myers Squibb's Assets	$ 86,708 million	BMY's Balance sheet
Bristol Myers Squibb's Income	$ 3,316 million	Quarterly BMY's Income Statement
BMY's Income by Division		See BMY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2.34 %	-4.36 %	-3.23 %	-12.66 %	-7.74 %
Total Assets in million	90,434	88,367	92,391	95,476	109,314
Y / Y Net Income Change	-	-	26.71 %	-9.54 %	-
Net Income in million	7,055	-8,933	8,040	6,345	7,014
Annual Return On Assets	7.8 %	-10.11 %	8.7 %	6.65 %	6.42 %

BMY's 5 Years Annual ROA >> Back to BMY Management Effectiveness >> Compare BMY ROA to its Competitors

Comment on BMY's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 7.8 % compared to prior year, due to annual net income growth of % to $7,055.00 million, while value of Bristol Myers Squibb's overall assets grew just by 2.34 % to $90,434.00 million, compared to $90,434.00 a year before.

More Return On Assets Ratios
BMY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BMY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BMY's Competitors
Subscribers only: Roa for Bristol Myers Squibb's Suppliers
Subscribers only: Return On Assets for BMY's Customers

You may also want to know
BMY's Roi	BMY's Inventory Turnover Ratio	BMY's Growth Rates	BMY's Dividend Comparisons
	BMY's Profitability Ratios	BMY's Asset Turnover Ratio	BMY's Dividend Growth
BMY's Roe	BMY's Valuation Ratios	BMY's Financial Strength Ratios	BMY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %

Date modified: 2026-09-14T03:49:14+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.